MedTrace Logo

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

NCT02047903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 161

Last updated 2020-01-09

Study results available
· View outcomes & findings →

Summary

This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR-mutations. Eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with GIOTRIF in first line according to the local label, will be followed up for approximately 24 months.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Afatinib

50, 40, 30 or 20 mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-05
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02047903 on ClinicalTrials.gov